It's a truism in the stock market that winners tend to keep winning. For pharmaceutical companies, making good on that axiom requires a lot of hard work to develop new medicines, and to find ways of adding to established markets that are addressable by their existing drug portfolios.

But the best competitors do it anyway, again and again. So let's examine a pair of today's leading drug businesses and see how they're building up their leading products to make them (and investors) even more cash.

Thanks to its smash-hit drugs for type 2 diabetes and obesity, Mounjaro and Zepbound, Eli Lilly (NYSE: LLY) is on a tear. In the first quarter, its revenue jumped by 26% to nearly $8.8 billion thanks to white-hot demand for those two medicines in particular. And the sales potential for both drugs just got even better, again, which supports the core investing thesis for this stock.

Continue reading

Source Fool.com